Apyx Medical Corporation (APYX) – What Are Brokerages Thinking About This Stock?

Apyx Medical Corporation (NASDAQ:APYX) has been assigned an average recommendation of “Moderate Buy” from the eight brokerages that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $6.50.

APYX has been the subject of a number of recent analyst reports. Maxim Group assumed coverage on shares of Apyx Medical in a report on Tuesday, September 29th. They issued a “buy” rating and a $6.00 target price for the company. HC Wainwright began coverage on shares of Apyx Medical in a research note on Monday, July 13th. They set a “buy” rating and a $7.00 price target on the stock. Zacks Research raised shares of Apyx Medical to a “hold” rating in a research note on Tuesday, July 14th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Apyx Medical in a report on Monday, September 21st.

Apyx Medical Stock Up 2.9%

Shares of NASDAQ APYX opened at $2.51 on Thursday. Apyx Medical has a 12-month low of $2.32 and a 12-month high of $5.08. The company has a market capitalization of $105.72 million, a PE ratio of -12.55 and a beta of 1.45. The company has a debt-to-equity ratio of 3.19, a current ratio of 5.68 and a quick ratio of 4.53. The firm’s 50-day moving average is $2.85 and its two-hundred day moving average is $3.61.

Apyx Medical (NASDAQ:APYX) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.01. The business had revenue of $13.88 million for the quarter, compared to the consensus estimate of $13.18 million. Apyx Medical had a negative return on equity of 76.60% and a negative net margin of 14.78%. Equities analysts anticipate that Apyx Medical will post -0.25 EPS for the current fiscal year.

Institutional Trading of Apyx Medical

Large investors have recently added to or reduced their stakes in the stock. Nwam LLC purchased a new stake in Apyx Medical during the 1st quarter worth $47,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in Apyx Medical in the 2nd quarter worth $62,000. AXQ Capital LP acquired a new position in Apyx Medical in the 2nd quarter worth $78,000. Jefferies Financial Group Inc. acquired a new position in Apyx Medical in the 2nd quarter worth $110,000. Finally, Squarepoint Ops LLC purchased a new position in Apyx Medical in the 2nd quarter valued at about $144,000. 55.33% of the stock is currently owned by institutional investors and hedge funds.

About Apyx Medical

Apyx Medical Corporation (NASDAQ: APYX) is a medical technology company that develops, manufactures and markets advanced energy systems for use in surgical and aesthetic procedures. The company’s products are based primarily on its proprietary Helium Plasma technology, which combines helium gas and radiofrequency energy to deliver controlled thermal effects to soft tissue.

Its principal product platform is Renuvion, a system designed for use by physicians in soft-tissue procedures. The platform includes generators, handpieces and related accessories intended to support tissue coagulation, cutting, dissection and contraction in various surgical and aesthetic applications.